Several studies have shown TP53 mutations are frequently detected in patients with therapy-related acute myeloid leukemia (AML)7 or AML with complex karyotype (AML-CK).8, 9, 10 The incidences of this mutation in AML-CK varied from 53% in a British series,10 to 60–69% in two German studies.8, 9 In contrast, TP53 mutations rarely occurred in patients without CK (2.1%)8 or 17p chromosomal abnormality (2.8%).11 The reports regarding the prognostic relevance of TP53 mutations in patients with AML-CK showed controversial results. Here, TP53 is linked to acute myeloid leukemia.